Based on the analysis of Regenxbio's profitability, liquidity, and operating efficiency, Regenxbio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Regenxbio's Property Plant Equipment is fairly stable compared to the past year. Property Plant And Equipment Gross is likely to rise to about 255.8 M in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 54.5 M in 2025. Key indicators impacting Regenxbio's financial strength include:
The essential information of the day-to-day investment outlook for Regenxbio includes many different criteria found on its balance sheet. An individual investor should monitor Regenxbio's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Regenxbio.
Please note, the imprecision that can be found in Regenxbio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Regenxbio. Check Regenxbio's Beneish M Score to see the likelihood of Regenxbio's management manipulating its earnings.
Regenxbio Stock Summary
Regenxbio competes with Day One, Replimune, Mirum Pharmaceuticals, Rocket Pharmaceuticals, and Avidity Biosciences. REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland. Regenxbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 372 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Regenxbio. It measures of how well Regenxbio is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Regenxbio brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Regenxbio had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Regenxbio has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Regenxbio's current stock value. Our valuation model uses many indicators to compare Regenxbio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regenxbio competition to find correlations between indicators driving Regenxbio's intrinsic value. More Info.
Regenxbio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Regenxbio's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Regenxbio's earnings, one of the primary drivers of an investment's value.
Regenxbio Systematic Risk
Regenxbio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Regenxbio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Regenxbio correlated with the market. If Beta is less than 0 Regenxbio generally moves in the opposite direction as compared to the market. If Regenxbio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Regenxbio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Regenxbio is generally in the same direction as the market. If Beta > 1 Regenxbio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Regenxbio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Regenxbio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Regenxbio growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Regenxbio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Regenxbio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Regenxbio based on widely used predictive technical indicators. In general, we focus on analyzing Regenxbio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Regenxbio's daily price indicators and compare them against related drivers.
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.